Aceto Strengthens Self-Manufacturing and Vaccine and Biopharmaceutical Offering With Acquisition of A&C 15th April 2021
Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced today its acquisition of A&C, a global GMP (Good Manufacturing Practices) manufacturer of specialty excipients, buffers, and process solutions. The acquisition helps to drive Aceto’s growth strategy, increasing the company’s GMP manufacturing, packaging, and ingredients offerings for the cell culture, vaccine, and biopharmaceutical industries, while also expanding its North American footprint.
A&C solves customers’ technical, product and regulatory challenges through GMP custom ingredient development, manufacturing, and packaging in the life science sector. With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.
“With the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,” said Gilles Cottier, Chief Executive Officer of Aceto. “Across all of our recent acquisitions, including Syntor and IsleChem, Aceto can now offer customers an extensive selection of highest quality and competitively priced products and services to help customers secure and optimize critical supply as well as bring new products to market globally.”
“A&C is a service-driven organization with a mission of finding unique solutions to customers’ GMP challenges and supporting them through all stages of the development cycle,” said Ken McCracken, President & CEO of A&C. “This fundamental approach to our business perfectly aligns with Aceto’s value proposition and customer-centric service philosophy. We are excited to provide customers a differentiated, integrated suite of product offerings.”
Aceto will continue to support A&C’s manufacturing facilities and offices in the USA, Canada, and Ireland. Financial terms were not disclosed.